Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus ETODOLAC.
Head-to-head clinical analysis: EC NAPROSYN versus ETODOLAC.
EC-NAPROSYN vs ETODOLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
500-1000 mg orally twice daily; maximum 1500 mg/day.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Extended-release: 400-1000 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Clinical Note
moderateEtodolac + Gatifloxacin
"Etodolac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateEtodolac + Rosoxacin
"Etodolac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateEtodolac + Levofloxacin
"Etodolac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateEtodolac + Trovafloxacin
"Etodolac may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is approximately 6.5-7.5 hours (range 5-8 hours). With multiple dosing, the half-life remains unchanged, indicating linear kinetics. No accumulation in normal renal function.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Renal excretion (72% as metabolites, including glucuronides and hydroxylated derivatives, less than 1% unchanged); fecal excretion (16%, primarily as metabolites); biliary excretion contributes to enterohepatic recirculation.
Category C
Category D/X
NSAID
NSAID